Summary
Humanized monoclonal antibodies (mAbs) against HER2 including trastuzumab and pertuzumab are widely used to treat HER2 overexpressing metastatic breast cancers. These two mAbs recognize distinct epitopes on HER2 and their combination induces a more potent blockade of HER2 signaling than trastuzumab alone. Recently, we have reported characterization of a new chimeric mAb (c-1T0) which binds to an epitope different from that recognized by trastuzumab and significantly inhibits proliferation of HER2 overexpressing tumor cells. Here, we describe humanization of this mAb by grafting all six complementarity determining regions (CDRs) onto human variable germline genes. Humanized VH and VL sequences were synthesized and ligated to human γ1 and κ constant region genes using splice overlap extension (SOE) PCR. Subsequently, the humanized antibody designated hersintuzumab was expressed and characterized by ELISA, Western blot and flow cytometry. The purified humanized mAb binds to recombinant HER2 and HER2-overexpressing tumor cells with an affinity comparable with the chimeric and parental mouse mAbs. It recognizes an epitope distinct from those recognized by trastuzumab and pertuzumab. Binding of hersintuzumab to HER2 overexpressing tumor cells induces G1 cell cycle arrest, inhibition of ERK and AKT signaling pathways and growth inhibition. Moreover, hersintuzumab could induce antibody-dependent cell cytotoxicity (ADCC) on BT-474 cells. This new humanized mAb is a potentially valuable tool for single or combination breast cancer therapy.
Similar content being viewed by others
References
Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177–184. https://doi.org/10.1016/j.ceb.2008.12.010
Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59(9):1295–1312. https://doi.org/10.1007/s00262-010-0869-2
Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316(7):1083–1100. https://doi.org/10.1016/j.yexcr.2010.01.009
Amiri MM, Jeddi-Tehrani M, Kazemi T, Bahadori M, Maddah M, Hojjat-Farsangi M, Khoshnoodi J, Rabbani H, Shokri F (2013) Construction and characterization of a new chimeric antibody against HER2. Immunotherapy 5(7):703–715. https://doi.org/10.2217/imt.13.67
Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T (2012) Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-alpha. BMC Cancer 12:450. https://doi.org/10.1186/1471-2407-12-450
Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. https://doi.org/10.1056/NEJMoa1113216
Traynor K (2012) FDA approves pertuzumab for breast cancer. Am J Health Syst Pharm 69(14):1178. https://doi.org/10.2146/news120049
Kazemi T, Tahmasebi F, Bayat AA, Mohajer N, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, Shokri F (2011) Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma (Larchmt) 30(4):347–353. https://doi.org/10.1089/hyb.2011.0023
Tahmasebi F, Kazemi T, Amiri MM, Khoshnoodi J, Bayat AA, Jeddi-Tehrani M, Rabbani H, Shokri F (2014) In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. Immunotherapy 6(1):1–7
Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45(2):879–885
Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15(1):42–52
Marcatili P, Rosi A, Tramontano A (2008) PIGS: automatic prediction of antibody structures. Bioinformatics 24(17):1953–1954. https://doi.org/10.1093/bioinformatics/btn341
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33–38 27-38
Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y (2008) Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling. J Biochem 144(1):115–120. https://doi.org/10.1093/jb/mvn052
Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619–1633
Hu WG, Chau D, Wu J, Jager S, Nagata LP (2007) Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 25(16):3210–3214. https://doi.org/10.1016/j.vaccine.2007.01.034
Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci 86(24):10029–10033
Jones ML, Barnard RT (2005) Chimerization of multiple antibody classes using splice overlap extension PCR. BioTechniques 38(2):181–182
Saboor-Yaraghi AA, Ghods R, Gharagozlou S, Roohi A, Khoshnoodi J, Towfighi F, Jeddi-Tehrani M, Shokri F (2004) Identification of cross-reactive and restricted epitopes localized on human chorionic gonadotropin beta-subunit by monoclonal antibodies. Hybrid Hybridomics 23(2):101–107. https://doi.org/10.1089/153685904774129702
García-Morales P, Hernando E, Carrasco-García E, Menéndez-Gutierrez MP, Saceda M, Martínez-Lacaci I (2006) Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5(9):2172–2181
Caromile LA, Dortche K, Rahman MM, Grant CL, Stoddard C, Ferrer FA, Shapiro LH (2017) PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal 10(470). https://doi.org/10.1126/scisignal.aag3326
Yeung YG, Stanley ER (2009) A solution for stripping antibodies from polyvinylidene fluoride immunoblots for multiple reprobing. Anal Biochem 389(1):89–91. https://doi.org/10.1016/j.ab.2009.03.017
Abhinandan KR, Martin AC (2007) Analyzing the "degree of humanness" of antibody sequences. J Mol Biol 369(3):852–862. https://doi.org/10.1016/j.jmb.2007.02.100
Harris LJ, Larson SB, Hasel KW, McPherson A (1997) Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36(7):1581–1597. https://doi.org/10.1021/bi962514+
Burmester J, Spinelli S, Pugliese L, Krebber A, Honegger A, Jung S, Schimmele B, Cambillau C, Pluckthun A (2001) Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv fragments from phage-displayed murine antibody libraries. J Mol Biol 309(3):671–685. https://doi.org/10.1006/jmbi.2001.4663
Fiszman GL, Jasnis MA (2011) Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer 2011:352182. https://doi.org/10.4061/2011/352182
Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(14):1594–1600. https://doi.org/10.1200/JCO.2011.37.4207
Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15(24):7479–7491. https://doi.org/10.1158/1078-0432.CCR-09-0636
Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE (1993) Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68(6):1140–1145
Drebin JA, Link VC, Greene MI (1988) Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2(3):273–277
Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52(10):2771–2776
Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157(2):220–233. https://doi.org/10.1111/j.1476-5381.2009.00190.x
De Groot AS, Martin W (2009) Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 131(2):189–201. https://doi.org/10.1016/j.clim.2009.01.009
Ahmadzadeh V, Farajnia S, Feizi MA, Nejad RA (2014) Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother 33(2):67–73. https://doi.org/10.1089/mab.2013.0080
Dennis MS (2010) CDR repair: A novel approach to antibody humanization. In: Current trends in monoclonal antibody development and manufacturing. Springer, New York, pp 9–28
Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV (2004) SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol Immunol 41(9):863–872. https://doi.org/10.1016/j.molimm.2004.03.041
Verhoeyen M, Milstein C, Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239(4847):1534–1536
Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, Kashmiri SV, Lim SM, Choi CW, Hong HJ (2006) Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem 281(11):6985–6992. https://doi.org/10.1074/jbc.M511165200
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069):522–525
Tiwari A, Khanna N, Acharya SK, Sinha S (2009) Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues. Vaccine 27(17):2356–2366. https://doi.org/10.1016/j.vaccine.2009.02.019
Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC (1997) Structural insights into the evolution of an antibody combining site. Science 276(5319):1665–1669
Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224(2):487–499
An Z (2011) Therapeutic monoclonal antibodies: from bench to clinic. Wiley, New York
Kipriyanov SM, Le Gall F (2004) Generation and production of engineered antibodies. Mol Biotechnol 26(1):39–60. https://doi.org/10.1385/MB:26:1:39
Graves SS, Goshorn SC, Stone DM, Axworthy DB, Reno JM, Bottino B, Searle S, Henry A, Pedersen J, Rees AR (1999) Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Clin Cancer Res 5(4):899–908
Li B, Wang H, Zhang D, Qian W, Hou S, Shi S, Zhao L, Kou G, Cao Z, Dai J (2007) Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem Biophys Res Commun 357(4):951–956
S-o L, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, Hansen HJ (1995) Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 32(17):1413–1427
Hu WG, Yin J, Chau D, Negrych LM, Cherwonogrodzky JW (2012) Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One 7(9):e45595. https://doi.org/10.1371/journal.pone.0045595
Kuroda D, Shirai H, Jacobson MP, Nakamura H (2012) Computer-aided antibody design. Protein Eng Des Sel 25(10):507–521. https://doi.org/10.1093/protein/gzs024
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89(10):4285–4289
Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55(6):717–727
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J (2008) Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins 70(3):938–949. https://doi.org/10.1002/prot.21551
Ko BK, Lee SY, Lee YH, Hwang IS, Persson H, Rockberg J, Borrebaeck C, Park D, Kim KT, Uhlen M, Lee JS (2015) Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol 9(2):398–408. https://doi.org/10.1016/j.molonc.2014.09.007
Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr (2003) The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278(26):23441–23450. https://doi.org/10.1074/jbc.M300848200
Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984. https://doi.org/10.1093/annonc/mdl475
Li R, Hu S, Chang Y, Zhang Z, Zha Z, Huang H, Shen G, Liu J, Song L, Wei W (2016) Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells. Int J Mol Sci 17(4):563. https://doi.org/10.3390/ijms17040563
Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7):2343–2346
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amiri, M.M., Golsaz-Shirazi, F., Soltantoyeh, T. et al. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition. Invest New Drugs 36, 171–186 (2018). https://doi.org/10.1007/s10637-017-0518-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-017-0518-0